These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9191872)

  • 1. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
    Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
    Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
    Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
    Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
    Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
    Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
    Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
    Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice.
    Cesano A; Visonneau S; Tran T; Santoli D
    Int J Oncol; 1999 Feb; 14(2):245-51. PubMed ID: 9917498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
    Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
    Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
    Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
    Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
    Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
    Cesano A; Visonneau S; Santoli D
    Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive therapy of canine metastatic mammary carcinoma with the human MHC non-restricted cytotoxic T-cell line TALL-104.
    Visonneau S; Cesano A; Jeglum KA; Santoli D
    Oncol Rep; 1999; 6(6):1181-8. PubMed ID: 10523677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
    Visonneau S; Cesano A; Torosian MH; Santoli D
    Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
    Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
    Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
    Cesano A; Visonneau S; Santoli D
    Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of a human cytotoxic T-cell line (TALL-104) in brain tumor xenografts.
    Geoerger B; Tang CB; Cesano A; Visonneau S; Marwaha S; Judy KD; Sutton LN; Santoli D; Phillips PC
    Neuro Oncol; 2000 Apr; 2(2):103-13. PubMed ID: 11303619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.
    Cesano A; Visonneau S; Cioé L; Clark SC; Rovera G; Santoli D
    J Clin Invest; 1994 Sep; 94(3):1076-84. PubMed ID: 8083348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy.
    Cesano A; Visonneau S; Cioé L; Clark SC; Santoli D
    Cancer Immunol Immunother; 1995 Mar; 40(3):139-51. PubMed ID: 7728772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a karyotypically normal cytotoxic leukemic T-cell line from a T-ALL sample engrafted in SCID mice.
    Cesano A; O'Connor R; Nowell PC; Lange B; Clark SC; Santoli D
    Blood; 1993 May; 81(10):2714-22. PubMed ID: 8490180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
    Cesano A; Visonneau S; Rovera G; Santoli D
    Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.